AGILENT TECHNOLOGIES, INC.
AAPI behind this page
A Q2 2026 request
Playground key active
/api/financials?ticker=A&year=2026&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2026 | Q2 2025 | YoY |
|---|---|---|---|
| Revenue | 1,835 | 1,668 | +10.0% |
Show Product Lines breakouts |
|||
| Instrumentation | 618 | 550 | +12.4% |
| Non-Instrumentation and Other | 1,217 | 1,118 | +8.9% |
| Product | 1,305 | 1,186 | +10.0% |
| Service Other | 530 | 482 | +10.0% |
Show Business Segments breakouts |
|||
| Agilent CrossLab | 759 | 713 | +6.5% |
| Agilent CrossLab · Americas | 289 | 270 | +7.0% |
| Agilent CrossLab · Asia Pacific | 248 | 249 | -0.4% |
| Agilent CrossLab · Europe | 222 | 194 | +14.4% |
| Agilent CrossLab · Operating Segments | 759 | 713 | +6.5% |
| Applied Markets | 344 | 301 | +14.3% |
| Applied Markets · Americas | 112 | 83 | +34.9% |
| Applied Markets · Asia Pacific | 150 | 147 | +2.0% |
| Applied Markets · Europe | 82 | 71 | +15.5% |
| Applied Markets · Operating Segments | 344 | 301 | +14.3% |
| Life Sciences and Diagnostics Markets | 732 | 654 | +11.9% |
| Life Sciences and Diagnostics Markets · Americas | 363 | 325 | +11.7% |
| Life Sciences and Diagnostics Markets · Asia Pacific | 155 | 152 | +2.0% |
| Life Sciences and Diagnostics Markets · Europe | 214 | 177 | +20.9% |
| Life Sciences and Diagnostics Markets · Operating Segments | 732 | 654 | +11.9% |
Show Geography breakouts |
|||
| Americas | 764 | 678 | +12.7% |
| Asia Pacific | 553 | 548 | +0.9% |
| Europe | 518 | 442 | +17.2% |
Show End Markets [Axis] breakouts |
|||
| Academia and Government Market | 132 | 135 | -2.2% |
| Chemicals and Advanced Materials Market | 412 | 369 | +11.7% |
| Diagnostics and Clinical Market | 295 | 255 | +15.7% |
| Environmental and Forensics Market | 186 | 159 | +17.0% |
| Food Market | 147 | 147 | 0.0% |
| Pharmaceutical and Biotechnology Market | 663 | 603 | +10.0% |
| Cost of Revenue | 845 | 802 | +5.4% |
Show Product Lines breakouts |
|||
| Product | 567 | 538 | +5.4% |
| Service Other | 278 | 264 | +5.3% |
Show Business Segments breakouts |
|||
| Agilent CrossLab · Operating Segments | 338 | 317 | +6.6% |
| Applied Markets · Operating Segments | 152 | 140 | +8.6% |
| Life Sciences and Diagnostics Markets · Operating Segments | 337 | 309 | +9.1% |
| Total Costs & Expenses | 1,436 | 1,368 | +5.0% |
| Research & Development | 126 | 112 | +12.5% |
Show Business Segments breakouts |
|||
| Agilent CrossLab · Operating Segments | 28 | 27 | +3.7% |
| Applied Markets · Operating Segments | 24 | 23 | +4.3% |
| Life Sciences and Diagnostics Markets · Operating Segments | 64 | 59 | +8.5% |
| Selling, General & Administrative | 465 | 454 | +2.4% |
Show Business Segments breakouts |
|||
| Agilent CrossLab · Operating Segments | 151 | 138 | +9.4% |
| Applied Markets · Operating Segments | 88 | 79 | +11.4% |
| Life Sciences and Diagnostics Markets · Operating Segments | 170 | 157 | +8.3% |
| Operating Expenses (Q) | — | — | — |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 84 | 119 | -29.4% |
| Operating Income | 399 | 300 | +33.0% |
Show Business Segments breakouts |
|||
| Agilent CrossLab · Operating Segments | 242 | 231 | +4.8% |
| Applied Markets · Operating Segments | 80 | 59 | +35.6% |
| Life Sciences and Diagnostics Markets · Operating Segments | 161 | 129 | +24.8% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 483 | 419 | +15.3% |
| Interest Income | 13 | 14 | -7.1% |
| Other Non-Operating Income (Expense) | 21 | -25 | +184.0% |
| Income Before Taxes | 408 | 260 | +56.9% |
| Income Tax Expense (Benefit) | 69 | 45 | +53.3% |
| Net Income | 339 | 215 | +57.7% |
Show Equity Components breakouts |
|||
| Parent | 339 | 215 | +57.7% |
| Retained Earnings | 339 | 215 | +57.7% |
| Comprehensive Income (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Parent | 321 | 316 | +1.6% |
| EPS (Basic) | 1.2 | 0.75 | +60.0% |
| EPS (Diluted) | 1.2 | 0.75 | +60.0% |
| Wtd Avg Shares (Basic) | 282 | 285 | -1.1% |
| Wtd Avg Shares (Diluted) | 283 | 285 | -0.7% |
| Interest Expense | -25 | -29 | +13.8% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax | 5 | -14 | +135.7% |
Balance Sheet
| Metric | Q2 2026 | Q2 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,807 | — | — |
| Accounts Receivable | 1,498 | — | — |
| Inventory | 1,089 | — | — |
| Other Assets Current | 369 | — | — |
| Total Current Assets | 4,763 | — | — |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,099 | — | — |
| Goodwill | 4,484 | — | — |
Show Business Segments breakouts |
|||
| Agilent CrossLab | 1,172 | — | — |
| Applied Markets | 315 | — | — |
| Life Sciences and Diagnostics Markets | 2,997 | — | — |
| Long Term Investments | 136 | — | — |
| Other Non-Current Assets | 1,176 | — | — |
| Total Assets | 13,065 | — | — |
| Operating Lease Right-of-Use Assets | 181 | 182 | -0.5% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 407 | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Relationships | 149 | — | — |
| Developed Technology Rights | 229 | — | — |
| Order Or Production Backlog | 6 | — | — |
| Third-Party Technology and Licenses | 8 | — | — |
| Trademarks | 15 | — | — |
| Current Liabilities | |||
| Accounts Payable | 615 | — | — |
| Employee Related Liabilities Current | 387 | — | — |
| Deferred Revenue | 665 | — | — |
| Short Term Borrowings | 304 | — | — |
Show Debt Instrument breakouts |
|||
| Other Loans | 4 | — | — |
| Other Accrued Liabilities Current And Noncurrent | 298 | — | — |
| Total Current Liabilities | 2,269 | — | — |
| Current Portion of Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| Senior Notes 2026 · Senior Notes | 300 | — | — |
| Non-Current Liabilities | |||
| Long-Term Debt | 3,051 | — | — |
Show Debt Instrument breakouts |
|||
| Other Loans | 18 | — | — |
| Senior Notes | 3,033 | — | — |
| Senior Notes 2027 | 598 | — | — |
| Senior Notes 2029 | 497 | — | — |
| Senior Notes 2030 | 498 | — | — |
| Senior Notes 2031 | 846 | — | — |
| Senior Notes 2034 | 594 | — | — |
| Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent | 127 | — | — |
| Other Non-Current Liabilities | 496 | — | — |
| Total Liabilities | 5,943 | — | — |
| Stockholders' Equity | |||
| Common Stock | 3 | — | — |
| Additional Paid-In Capital | 5,629 | — | — |
| Retained Earnings | 1,692 | — | — |
| Accumulated Other Comprehensive Income | -202 | — | — |
| Total Stockholders' Equity | 7,122 | — | — |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -202 | -280 | +27.9% |
| Additional Paid In Capital | 5,629 | 5,501 | +2.3% |
| Common Stock | 3 | 3 | 0.0% |
| Parent | 7,122 | 6,136 | +16.1% |
| Retained Earnings | 1,692 | 912 | +85.5% |
| Total Liabilities & Equity | 13,065 | — | — |
Cash Flow Statement
| Metric | YTD Q2 2026 | YTD Q2 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 134 | 145 | -7.6% |
| Stock-Based Compensation | 73 | 70 | +4.3% |
| Deferred Income Taxes | 57 | -28 | +303.6% |
| Other Non-Cash Items | -4 | -2 | -100.0% |
| Change in Accounts Receivable | -6 | -27 | +77.8% |
| Change in Inventory | -85 | -41 | -107.3% |
| Change in Accounts Payable | 54 | -27 | +300.0% |
| Change in Deferred Revenue | 431 | 432 | -0.2% |
| Net Cash from Operations | 545 | 652 | -16.4% |
| Investing Activities | |||
| Capital Expenditures | -169 | -211 | +19.9% |
| Net Cash from Investing | -170 | -208 | +18.3% |
| Financing Activities | |||
| Share Repurchases | -217 | -255 | +14.9% |
| Tax Withholding for Share Compensation | 29 | 24 | +20.8% |
| Net Cash from Financing | -366 | -296 | -23.6% |
| Supplemental | |||
| Income Taxes Paid | 320 | 248 | +29.0% |
| Interest Paid | 45 | 51 | -11.8% |
| Other Cash Flow | |||
| Net Change in Cash | 18 | 157 | -88.5% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.